CClinicalTrials.gg
Status unknownNCT05314530ReTA-modelUpdated Apr 6, 2022

The ReTA-model: Rehabilitation Trail for Workers on Long-term Sick Leave in the Healthcare Sector

An interventional study of ReTA-model in Burnout, sponsored by Karolinska Institutet. Status unknown at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Sex
All
01

Study summary

The ReTA-model is a rehabilitation model for return to work after long-term sickness absence (LTSA) due to stress or burnout. The ReTA-model will be validated in this trial among nurses and physicians currently in LTSA. The ReTA-model includes a three-week treatment with exercise, individual and collegial talks with psychology and lecturing. The control group will receive conventional rehabilitation from regular care.

Read the detailed description

The ReTA-model is a rehabilitation model for return to work after long-term sickness absence (LTSA) due to stress or burnout. The ReTA-model will be validated in this trial among nurses and physicians currently in LTSA. The ReTA-model includes a three-week treatment with exercise, individual and collegial talks with psychology and lecturing. The control group will receive conventional rehabilitation from regular care.

02

Conditions studied

  • Burnout

Keywords

  • Healthcare
  • Burnout
  • Stress
  • Return to work
  • Intervention
03

In context

Burnout, Psychological

442 studies on the registry are indexed under Burnout, Psychological; 106 are open to participants now.

This study's planned enrollment of 64 is below the median of 80 across 319 interventional studies indexed under Burnout, Psychological.

Browse Burnout, Psychological studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • currently on sick leave for burnout
  • employed in the Swedish healthcare services as a nurse or as a physician

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Will receive a rehabilitation intervention

    Behavioral: ReTA-model

  • Active comparator
    Controll

    Will receive conventional rehabilitation

    Behavioral: ReTA-model

Interventions

  • BehavioralReTA-model

    Validating the rehabilitation model ReTA

06

What researchers measure

Primary outcomes

  1. Return to work

    At work part or full-time compare to no return to work

    Time frame: 12 months

  2. Karolinska Exhaustion Disorder Scale KEDS

    Decreased points in the KEDS scale 1-19, qith higher scores reflecting greater exhaustion severity.

    Time frame: 12 months

  3. Symptom Checklist - 6

    Decreased points on the SCL-6 scale, with a higher number reflecting depression.

    Time frame: 12 months

  4. Montgomery Åsberg Depression Rating Scale

    Decreased points in the MADRAS scale with score ranging from 0 to 60, with higher scores reflecting greater depression severity.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Karolinska Institutet
    Stockholm, Outside U.S. And Canada 171 77, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05314530
Lead sponsor
Karolinska Institutet
Responsible party
Emma Hagqvist (Associate Professor, Karolinska Institutet) — Principal investigator
First posted
Apr 6, 2022
Start date
Mar 1, 2022
Primary completion
Apr 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Apr 6, 2022

Study contacts

Emma Hagqvist, PhD
Contact
emma.hagqvist@ki.se
+46730526602
Åke Nygren, MD
Contact
Emma Hagqvist
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion